



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: A. Michael Lincoff, M.D.

Committee: Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC)

Meeting Date: January 9, 2018

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: New drug application (NDA) 206089 (oral testosterone undecanoate capsules) submitted by Clarus Therapeutics, for the proposed indication of testosterone replacement in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired), I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None.		
II. Other Imputed Interests		
Employer's research contracts	(b) (4), Competing firm	\$700,000 – \$750,000 total
	(b) (4), Competing firm	\$7,000,000 – \$7,500,000 total

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

____12/14/2017_____
Date